Dianthus Therapeutics, Inc. /De/ (DNTH) Stock Price & Analysis
Dianthus Therapeutics, Inc. /De/ (DNTH) rose 4.12% to USD 84.57 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
DNTH last closed at USD 81.22; the session ranged USD 78.64–84.84 on volume of 619,513 shares. Market capitalization is $4.62B, with a 52-week range of USD 16.64–96.5 (NCM). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 84.57 |
|---|---|
| Change | ▲ 4.12% (up) |
| Previous Close | USD 81.22 |
| Open | USD 82.43 |
| Day Range | USD 78.64 – 84.84 |
| 52-Week Range | USD 16.64 – 96.5 |
| Volume | 619,513 shares |
| Market Cap | $4.62B |
| Exchange | NCM |
Technical Analysis (DNTH)
Nexqual's technical model rates DNTH "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.17 (neutral) |
| vs SMA50 | Below (USD 87.44) |
| MACD | -0.86 (negative) |
Analyst Ratings (DNTH)
Wall Street analysts rate DNTH "Strong Buy" based on 12 analysts, with a mean price target of USD 125.83 (range USD 98–200), per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 125.83 |
| High Target | USD 200 |
| Low Target | USD 98 |
| Buy / Hold / Sell | 15 / 0 / 0 |
Earnings (DNTH)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD -0.91 |
| Revenue Estimate | $248,750 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.85 vs est -1.1 ▲ beat |
| 2025-12-31 | USD -1.43 vs est -1.03 ▼ miss |
| 2025-09-30 | USD -0.97 vs est -0.9 ▼ miss |
| 2025-06-30 | USD -0.88 vs est -0.87 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (DNTH)
| Total Revenue | $1.34M |
|---|---|
| Revenue Growth (YoY) | -60.20% |
| Gross Margin | +100.00% |
| Operating Margin | -10050.32% |
| Profit Margin | +0.00% |
| ROE | -22.70% |
| Debt / Equity | 0.11 |
| Current Ratio | 29.25 |
| Total Cash | $1.11B |
| Total Debt | $1.36M |
| Free Cash Flow | $-71.03M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (DNTH)
Nexqual rates Dianthus Therapeutics, Inc. /De/'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Critical — Revenue -67% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.11B cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$71M, burning cash |
| Efficiency | Critical — ROE -23%, ROA -15.0% |
Ownership (DNTH)
| Insider Ownership | +0.13% |
|---|---|
| Institutional Ownership | +120.33% |
| Shares Outstanding | 54.67M |
| Float | 54.60M |
| Short % of Float | +14.09% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (DNTH)
Dianthus Therapeutics, Inc. /De/ is led by Marino Garcia (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.
| President, CEO & Director | Marino Garcia (age 59) |
|---|---|
| Executive VP, CFO, Chief Business Officer & Treasurer | Ryan Savitz (age 36) |
Major Backers & Investors (DNTH)
Notable institutional backers of Dianthus Therapeutics, Inc. /De/ include FMR, LLC, Fidelity, RA Capital Management, L.P., according to Nexqual as of June 10, 2026 at 02:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.21% |
| Fidelity | 5.76% |
| RA Capital Management, L.P. | 4.78% |
| Wellington Management | 4.75% |
| Fairmount Funds Management LLC | 4.64% |
| Avidity Partners Management, LP | 3.85% |
| Octagon Capital Advisors LP | 3.56% |
| TCG Crossover Management, LLC | 3.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.46% |
| BlackRock | 7.35% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
From Dianthus Therapeutics, Inc. /De/'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.
Partnerships
- Our First and Potentially Best-In-Class Bifunctional BDCA2 and BAFF/APRIL Inhibitor (DNTH212) On October 16, 2025, we entered into an exclusive license agreement with Nanjing Leads Biolabs Co., Ltd. ("Leads") for DNTH212, a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor.
- We are currently a party to a license agreement with Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia") for claseprubart, pursuant to which Tenacia has development and commercialization rights in the People's Republic of China, including Hong Kong, Macau, and Taiwan ("Greater China").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | USD 76.44 | ▲ 3.79% |
| ELVN | Enliven Therapeutics, Inc. | USD 36.11 | ▲ 4.03% |
| APGE | Apogee Therapeutics, Inc. | USD 85 | ▼ 2.21% |
| ORKA | Oruka Therapeutics, Inc. | USD 66.93 | ▲ 11.29% |
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.